Biotech IV Monitor

TRVI — Trevi Therapeutics Inc.

$2.5B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Trevi Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.

Next readoutAugust 2027in ~9 months
Upcoming readouts32 Phase 3
Market cap$2.5B
Cash & investments$299M~14 quarters at last loss rate
Recent 8-K filings1latest 2026-11-09

Upcoming readouts

Phase 3 NAL ER
Idiopathic Pulmonary Fibrosis · NCT07868419
August 2027
Recruiting
Phase 2 NAL ER
Refractory Chronic Cough · NCT07671924
September 2027
Recruiting
Phase 3 NAL ER
Idiopathic Pulmonary Fibrosis · NCT07671911
June 2028
Recruiting

Cash position

Trevi Therapeutics Inc. reported $299M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $21M; at that rate the cash would last about 14 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-09

Companies working on similar indications

Discussion

No messages yet. If you follow TRVI, you can start the conversation.
Track TRVI in real time
See live implied volatility for TRVI and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TRVI
Contact — questions or corrections about TRVI: dukeupt@gmail.com